Reveal the binding targets of ‘orphan antibodies’ by screening against 6,000 human membrane proteins
Advances in high-throughput functional screening allow for the isolation of antibodies with desired functions, but whose binding targets may remain unknown. Determining the targets for such phenotypic antibodies (deorphaning) is key to understanding antibody mechanism of action and to progress therapeutic development. Similarly, deorphaning of patient-derived antibodies can identify new targets for autoimmune diseases or oncology.
Integral Molecular's Membrane Proteome Array (MPA) is the leading technology to deorphan antibodies obtained by phenotypic screening. With 6,000 human membrane proteins individually expressed in unfixed cells, the MPA represents the largest set of human membrane proteins assembled, encompassing 95% of the human membrane proteome. The MPA is ideal for target deconvolution and has been used to identify previously unknown targets for antibodies, scFvs, and patient serum samples.
Features of the Membrane Proteome Array
- 6,000 membrane proteins representing ~95% of the membrane proteome
- Native-conformation target proteins expressed in live cells with appropriate post-translational modifications
- Binding interactions tested using sensitive high-throughput flow cytometry
- Target validation by secondary titration analysis
Identifying novel cancer targets
Learn how Totient (now AbSci) used the MPA to deorphan intratumoral antibodies and identify potential oncology